IXICO plc
(“IXICO”, the “Company” or the “Group”)
IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease
17 November 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces the presentation of new research in Alzheimer’s disease (AD) at the 19th Clinical Trials on Alzheimer’s Disease Conference 2026 (CTAD).
The research developed and evaluated an artificial intelligence (AI) tool to support radiologists in detecting cerebral microbleeds (CMBs) on magnetic resonance imaging (MRI) scans. CMBs are tiny deposits of blood in the brain that appear as small dark spots on an MRI. They are important in AD clinical trials and treatment, because pre-existing and new microbleeds are a key vascular safety concern with anti-amyloid therapies, and patients must be monitored with repeated MRI scans. Identifying CMBs by eye is time-consuming and can vary between radiologists, which is where the newly developed tool presents a potentially significant improvement in efficiency and accuracy.
The tool works in two stages: it first finds possible microbleeds across the whole brain, then examines each one to separate true CMBs from similar-looking structures such as blood vessels. On average, the IXICO developed tool detected around 90% of the microbleeds in each participant’s scan, comparing favourably to other published results, and performed consistently across studies and imaging techniques.
Robin Wolz, Chief Scientific Officer of IXICO, commented: “As new treatments for Alzheimer’s disease become increasingly available, the ability to monitor patient safety accurately and efficiently is more important than ever. Detecting cerebral microbleeds is a critical part of this process but remains a time-consuming task that can be subject to variability between radiologists. Our research demonstrates the potential of AI to transform this process, delivering high levels of accuracy and consistency across different MRI techniques and patient populations. This is another example of how IXICO is applying its deep expertise in neuroscience and AI to address real-world challenges in drug development and help bring new therapies to patients.”
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the platform and IXICO’s expert scientists translating complex data into clinically meaningful insights while minimizing data variability and increasing reproducibility.